Benefit of adjuvant immunotherapy in renal cell carcinoma: A myth or a reality?

• Satoru Taguchi,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Sebastiano Buti,

  Affiliation Medical Oncology Unit, University Hospital of Parma, Parma, Italy

  ⨯
• Hiroshi Fukuhara ,

  * E-mail: hfukuhara-jua@umin.ac.jp

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Masafumi Otsuka,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Melissa Bersanelli,

  Affiliation Medical Oncology Unit, University Hospital of Parma, Parma, Italy

  ⨯
• Teppei Morikawa,

  Affiliation Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Hideyo Miyazaki,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Tohru Nakagawa,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Tetsuya Fujimura,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Haruki Kume,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Yasuhiko Igawa,

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯
• Yukio Homma

  Affiliation Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  ⨯